Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Howe

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Journal of Medicinal Chemistry|November 10, 2009
In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in ratsFrançois Maltais, Young Chun Jung, Minzhang Chen, et al.
Science Translational Medicine|April 26, 2019
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunityJodi L Karnell, Marius Albulescu, Stacey Drabic, et al.
Annals of the Rheumatic Diseases|November 22, 2018
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responsesBo Chen, Katherine A Vousden, Brian Naiman, et al.
Journal of Medicinal Chemistry|August 1, 2015
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.
Vox Sanguinis|September 20, 2014
Aggregates in platelet concentratesPieter F van der Meer, L J Dumont, Miguel Lozano, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Journal of Medicinal Chemistry|November 10, 2009
In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in ratsFrançois Maltais, Young Chun Jung, Minzhang Chen, et al.
Science Translational Medicine|April 26, 2019
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunityJodi L Karnell, Marius Albulescu, Stacey Drabic, et al.
Annals of the Rheumatic Diseases|November 22, 2018
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responsesBo Chen, Katherine A Vousden, Brian Naiman, et al.
Journal of Medicinal Chemistry|August 1, 2015
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.
Vox Sanguinis|September 20, 2014
Aggregates in platelet concentratesPieter F van der Meer, L J Dumont, Miguel Lozano, et al.
Pageof 6